Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Beats on EPS, Stock Up 2.21%

Alnylam Pharmaceuticals reported a smaller-than-expected loss per share, which led to a positive stock reaction, with shares rising 2.21%. However, there was no revenue reported or guidance provided, leaving investors with limited insight into future performance. The earnings surprise on EPS may indicate better-than-anticipated cost management or operational efficiency.